Historical cah News Stories

Cardinal Health Ups FY26 EPS Outlook to $10+

Cardinal Health raised its FY2026 non‑GAAP EPS guidance to at least $10, citing strong Specialty and BioPharma growth, broad ContinuCare rollout, and successful contract transitions ahead of Medicare drug‑pricing changes—key developments that materially affect CAH shares.

Cardinal Health Surges: Q2 Beat, Guidance Raised!!

Cardinal Health (CAH) reported a strong Q2 FY2026 with a revenue beat, raised full-year EPS guidance, and signaled continued growth from higher-margin specialty services (Sonexus, BioPharma). Technical strength (RS Rating 91) and aggressive capital returns contrast with elevated debt and $4.3B opioid liabilities.